Researchers at the University of Geneva have developed a programmable drug system built from synthetic DNA strands that identifies cancer cells with unprecedented accuracy and releases powerful drugs only where they are needed. Published in Nature Biotechnology, the system works like two-factor authentication — it only activates when it detects two distinct tumor markers on a cell's surface, preventing damage to healthy tissue.
Led by Professor Nicolas Winssinger, the team engineered multiple DNA strands with separate functions: some bind to cancer markers while others carry toxic payloads. When both markers are present, the components assemble at that exact location and trigger a chain reaction that delivers the drug. If either marker is missing, the system remains inactive. In laboratory tests, the smart drug successfully targeted cancer cells while leaving neighboring healthy cells completely unaffected.
The system can also deliver multiple drugs simultaneously, potentially overcoming treatment resistance. Because the DNA molecules are much smaller than traditional antibodies, they penetrate tumor tissue more easily, opening a new path toward highly targeted cancer therapies.
